VELOCITY: An Anthrax Vaccine Clinical Study
Trial details
- Registry ID
- NCT03877926
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as AV7909 Anthrax Vaccine; NuThrax
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| VELOCITY: An Anthrax Vaccine Clinical StudyNCT03877926 | Emergent BioSolutions | Phase 3 | Completed | 2020-08-06Actual |
| A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose LevelsNCT01770743 | Emergent BioSolutions | Phase 2 | Completed | 2014-02Actual |
| Velocity 2: An Anthrax Vaccine and Antibiotics Clinical StudyNCT04067011 | Emergent BioSolutions | Phase 2 | Completed | 2020-03-05Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |